Advanced Pancreatic Cancer
Conditions
Interventions
Experimental Group:Tiaoqi Xiaoji formula combined with chemotherapy
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age between 18 and 75 years, with no restriction on gender; (2) Histologically or cytologically confirmed pancreatic ductal adenocarcinoma that meets the diagnostic criteria for locally advanced and metastatic pancreatic cancer; (3) According to the Eastern Cooperative Oncology Group (ECOG) performance status criteria (Zubrod-ECOG-WHO, ZPS), patients with an ECOG score of 0-2; (4) Patients with an expected survival of at least 3 months; (5) Patients with at least 1 measurable or assessable lesion; (6) Patients who voluntarily agree to participate in this study, sign the informed consent form, and have good compliance.
Exclusion criteria
Exclusion criteria: (1) Patients with other active malignant tumors; (2) Patients with severe primary diseases of the heart, brain, liver (serum bilirubin = 1.5 times the upper limit of normal), kidneys (serum creatinine = 1.5 times the upper limit of normal), hematopoietic system, etc., as judged by the investigator to be unsuitable for enrollment; (3) Patients with active infections or other serious complications that may affect the safety or outcome assessment of the trial; (4) Pregnant or breastfeeding women, or women planning pregnancy within the next 3 months; (5) Patients with known allergies to the investigational drug or its excipients; (6) Patients currently participating in other interventional clinical trials; (7) Patients with severe mental disorders, cognitive impairments, or communication difficulties that prevent them from completing questionnaire assessments and follow-ups; (8)Patients deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 scores ; | — |
Secondary
| Measure | Time frame |
|---|---|
| European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Pancreatic Cancer Module 26 Score;M. D. Anderson Symptom Inventory–Gastrointestinal Cancer Module Score;Hospital Anxiety and Depression Scale score Score;Eastern Cooperative Oncology Group Performance Status Score;Body Mass Index;Disease control rate;Objective response rate;Serum carbohydrate antigen 19-9 level;Neutrophil-to-Lymphocyte Ratio;Platelet-to-Lymphocyte Ratio; | — |
Countries
China
Contacts
Public ContactBo Pang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Outcome results
None listed